Hermetica Superfood Encyclopedia
The Short Answer
Digitalis purpurea contains cardiac glycosides—primarily digoxin, digitoxin, and purpurea glycosides A and B—that inhibit the myocardial Na+/K+-ATPase pump, increasing intracellular calcium and producing a positive inotropic effect. The purified pharmaceutical derivative digoxin, dosed orally at 0.125–0.25 mg/day, remains clinically validated for improving cardiac output in heart failure and controlling ventricular rate in atrial fibrillation, though the raw plant is acutely toxic with a narrow therapeutic index.
CategoryHerb
GroupEuropean
Evidence LevelPreliminary
Primary Keywordfoxglove digitalis purpurea
Foxglove — botanical close-up
Health Benefits
**Positive Inotropic Cardiac Support**
Cardiac glycosides such as digoxin and digitoxin enhance myocardial contractility by inhibiting Na+/K+-ATPase, raising intracellular Ca2+ via the Na+/Ca2+ exchanger; this mechanism underpins the pharmaceutical management of systolic heart failure.
**Ventricular Rate Control in Atrial Fibrillation**
Digoxin exerts negative chronotropic and dromotropic effects through vagal stimulation and direct AV node slowing, reducing ventricular response rate in atrial fibrillation and improving hemodynamic stability.
**Historical Diuretic and Edema Relief**
Traditional leaf preparations were used to resolve dropsy (congestive edema) by improving cardiac output sufficiently to restore renal perfusion and promote natriuresis, an effect recognized empirically before cardiac pharmacology was understood.
**Cytotoxic Activity Against Cancer Cell Lines**
Four cardenolides isolated from D. purpurea seeds demonstrated IC50 values of 0.060–0.069 µM against HL-60 human promyelocytic leukemia cells in vitro, suggesting potential oncological applications that remain under preclinical investigation.
**Hepatoprotective Properties**
Methanolic leaf extracts reduced CCl4-induced hepatotoxicity in rat models, significantly lowering serum SGOT, SGPT, alkaline phosphatase, and bilirubin levels, an effect tentatively attributed to phenylethanoid glycosides including acteoside.
**Antioxidant Activity**: D
purpurea extracts exhibit high free-radical scavenging capacity—94.25% DPPH inhibition and 92.28% total antioxidant activity at 1 mg/mL—linked to flavonoids, phenolic acids, and phenylethanoid glycosides such as acteoside and purpureaside B.
**GST Induction and Chemoprotection**: Acteoside from D
purpurea induces glutathione S-transferase (GST) activity in hepatic cell lines, enhancing Phase II detoxification and demonstrating protection against aflatoxin B1-induced cytotoxicity in H4IIE cells.
Origin & History
Natural habitat
Digitalis purpurea is native to western and central Europe, thriving in hedgerows, woodland edges, and disturbed soils from the British Isles through the Iberian Peninsula and into Scandinavia. It is a biennial or short-lived perennial that favors acidic, well-drained soils in partial shade, commonly colonizing post-clearance woodland and roadsides at altitudes up to 1,500 meters. Historically cultivated in physic gardens across Britain and continental Europe since the 16th century, it was formalized as a medicinal source plant by William Withering in Shropshire, England, where rural herbalists had long employed it for dropsy.
“Foxglove occupies a singular position in Western medical history as the plant whose systematic study by physician-botanist William Withering in Shropshire, England, initiated the era of rational pharmacotherapy; his 1785 monograph 'An Account of the Foxglove and Some of Its Medical Uses' described its use in dropsy based on a folk remedy he obtained from a herbalist named Mrs. Hutton, representing one of the earliest evidence-informed plant medicine investigations. Prior to Withering, the plant appeared in Welsh herbal tradition as 'Menyg Ellyllon' (fairy gloves), used in poultices for skin ulcers and as a component in complex folk remedies, though internal use was recognized as dangerous. Medieval European herbalists including Leonhart Fuchs, who first formally described D. purpurea in 1542 and coined the genus name from the Latin 'digitalis' (finger-like, referring to flower shape), catalogued it but cautioned against internal use. Through the 19th and 20th centuries, chemists Nativelle (1869), Schmiedeberg, and later Stoll isolated the active glycosides, transforming foxglove from a hazardous folk remedy into the foundation of cardiac pharmacology and the progenitor of an entire drug class.”Traditional Medicine
Scientific Research
The clinical evidence base for Digitalis purpurea as a raw botanical is essentially historical and preclinical; no modern randomized controlled trials have evaluated whole-plant or standardized D. purpurea extracts in human subjects with defined sample sizes and effect sizes. The extensive clinical evidence that does exist pertains to the purified pharmaceutical isolate digoxin: landmark trials such as the DIG Trial (n=6,800) established digoxin's capacity to reduce heart failure hospitalizations without mortality benefit, but this evidence applies to the isolated compound rather than the plant itself. In vitro cytotoxicity data for seed-derived cardenolides (IC50 0.038–0.069 µM vs. HL-60 cells) and rat hepatoprotection studies with methanolic extracts represent the sum of contemporary experimental data on the crude plant, none of which include human sample sizes or prospectively defined endpoints. The evidence gap between the well-characterized pharmaceutical derivative and the unprocessed botanical is substantial, and the raw plant is not used in any contemporary evidence-based clinical protocol.
Preparation & Dosage
Traditional preparation
**Historical Dried Leaf Powder (Digitalis folium)**
1–2 g/day of powdered dried leaves used historically; now obsolete due to unpredictable glycoside concentrations and toxicity risk
**Historical Tincture**
Aqueous-alcoholic leaf extracts standardized crudely by bioassay in the 19th–early 20th century; replaced by isolated compounds
**Pharmaceutical Digoxin Tablets**
25 mg/day orally for heart failure or rate control in atrial fibrillation; loading doses of 0
0.125–0..5–1.0 mg in divided doses may be used under medical supervision
**Pharmaceutical Digoxin Injection**
5 mg IV for acute rate control; reserved for hospital settings with monitoring
0.25–0.
**Standardization Note**
No botanical supplement standardization exists; pharmaceutical digoxin is assayed to ≥95% purity; therapeutic serum levels 0.5–2.0 ng/mL with toxicity risk above 2.0 ng/mL
**Bioavailability Consideration**
Oral digoxin bioavailability approximately 70%; renal clearance necessitates dose reduction in impaired renal function
**Self-Supplementation Warning**
Raw plant, teas, tinctures, or unregulated extracts of D. purpurea must not be self-administered under any circumstances due to life-threatening toxicity
Nutritional Profile
Digitalis purpurea is not a nutritional food ingredient and has no meaningful dietary macronutrient or micronutrient profile relevant to human nutrition. Its phytochemical composition is dominated by cardenolide cardiac glycosides (up to 2% dry leaf weight), with glucoevatromonoside comprising approximately 30% of total cardenolides, digoxin present at up to 246.58 mg/kg dry leaf weight in peak-season specimens, and digitoxigenin at 11–241 mg/kg and gitoxigenin at 4–178 mg/kg in fresh leaves of two-year-old plants. Secondary phytochemicals include over 27 flavonoids, 14 phenolic acids, 15 phenylethanoid glycosides (notably acteoside), anthraquinones, saponins, and minor steroids totaling 55 identified compounds across the genus. Heavy metal contamination has been documented in some wild-collected samples, with lead concentrations of 4.70–8.19 µg/g, which represents an additional safety concern for any non-pharmaceutical preparation.
How It Works
Mechanism of Action
The primary mechanism of Digitalis purpurea cardiac glycosides centers on selective, reversible inhibition of the alpha-subunit of the sarcolemmal Na+/K+-ATPase (sodium-potassium pump) in cardiac myocytes; this raises intracellular Na+ concentration, which secondarily reduces Ca2+ extrusion through the Na+/Ca2+ exchanger (NCX), elevating cytosolic Ca2+ and augmenting actin-myosin crossbridge cycling to produce a positive inotropic effect. Negative chronotropic and dromotropic effects arise through two pathways: enhanced vagal (parasympathetic) tone via cardiopulmonary baroreceptor sensitization, and direct depression of sinoatrial and atrioventricular nodal conduction velocity through K+ channel modulation. At the cellular signaling level, cardiac glycosides also interact with membrane-bound Na+/K+-ATPase as a signal transducer, activating Src kinase and downstream EGFR/Ras/ERK cascades implicated in the observed cytotoxic and antiproliferative effects against tumor cell lines. Phenylethanoid glycosides such as acteoside operate through distinct pathways—upregulating GST gene expression, scavenging reactive oxygen species, and modulating NF-κB inflammatory signaling—contributing to antioxidant and hepatoprotective secondary activities.
Clinical Evidence
No prospective human clinical trials have been conducted on Digitalis purpurea plant material or standardized botanical extracts; clinical data originates entirely from the pharmaceutical history of purified cardiac glycosides derived from this species. William Withering's 1785 observational series in 'An Account of the Foxglove' documented resolution of dropsy in over 150 patients using leaf decoctions, representing the first systematic documentation but without control groups or quantified effect sizes by modern standards. Preclinical studies in rats using CCl4 hepatotoxicity models demonstrated statistically significant reductions in liver enzyme markers (SGOT, SGPT, ALP, bilirubin) with methanolic D. purpurea extract, but methodology, sample sizes, and confidence intervals are not fully reported in available literature. Overall clinical confidence in D. purpurea as a botanical ingredient is low; its medical relevance is mediated entirely through isolated derivatives subject to rigorous pharmaceutical regulation and therapeutic drug monitoring.
Safety & Interactions
Digitalis purpurea is one of the most acutely toxic medicinal plants in the European flora, with a narrow therapeutic index that makes the margin between therapeutic and lethal doses extremely small; toxic effects include nausea, vomiting, bradycardia, heart block, ventricular arrhythmias, hyperkalemia, and characteristic visual disturbances (xanthopsia—yellow-green halos around lights), and fatalities from accidental ingestion are documented even from modest quantities of raw leaf material. Critical drug interactions include potentiation of toxicity by loop and thiazide diuretics (through hypokalemia, which sensitizes Na+/K+-ATPase to glycoside inhibition), quinidine and verapamil (which displace digoxin from tissue binding and reduce renal clearance, raising plasma levels by up to 50%), and additive AV-nodal depression with beta-blockers and non-dihydropyridine calcium channel blockers; concurrent use of these agents with any digitalis preparation requires close monitoring. Contraindications include ventricular fibrillation, second- or third-degree AV block without pacing, hypertrophic obstructive cardiomyopathy, Wolff-Parkinson-White syndrome, and significant renal impairment due to reduced glycoside clearance; the plant and any of its preparations are absolutely contraindicated in pregnancy and lactation. No safe supplemental dose exists for the raw plant or unregulated extract; only pharmaceutical-grade digoxin under physician supervision with therapeutic drug monitoring (target serum level 0.5–2.0 ng/mL) is appropriate for any medical application.
Synergy Stack
Hermetica Formulation Heuristic
Also Known As
Digitalis purpureaCommon FoxglovePurple FoxgloveFairy GlovesMenyg EllyllonDigitalis foliumWitch's GlovesDead Men's Bells
Frequently Asked Questions
Is foxglove safe to consume or take as a supplement?
Foxglove (Digitalis purpurea) is not safe to consume as a food, tea, or unregulated supplement under any circumstances. The raw plant contains cardiac glycosides including digoxin and digitoxin at concentrations (up to 246 mg/kg dry leaf weight) capable of causing fatal cardiac arrhythmias, bradycardia, and heart block even in small quantities. Only pharmaceutical-grade purified digoxin, prescribed and monitored by a physician with regular blood level testing, is an appropriate medical application of this plant's chemistry.
What drug is made from foxglove plants?
The primary pharmaceutical drugs derived from Digitalis purpurea are digoxin and digitoxin, both cardiac glycosides used in conventional medicine. Digoxin (typically dosed at 0.125–0.25 mg/day orally) is prescribed for systolic heart failure to improve cardiac contractility and for atrial fibrillation to slow ventricular rate by inhibiting the Na+/K+-ATPase pump in heart muscle cells. These isolated compounds are produced under strict pharmaceutical manufacturing standards rather than from raw plant preparations.
How did William Withering discover foxglove's medicinal use?
In 1775, physician William Withering encountered a folk remedy for dropsy (congestive heart failure with edema) used by a herbalist named Mrs. Hutton in Shropshire, England, which contained Digitalis purpurea among over 20 ingredients. He systematically isolated the plant as the active component and spent the next decade documenting its effects in over 150 patients before publishing 'An Account of the Foxglove and Some of Its Medical Uses' in 1785. This work is considered one of the foundational texts of evidence-based pharmacotherapy and introduced digitalis to mainstream medicine.
What are the toxic effects of foxglove poisoning?
Foxglove poisoning produces symptoms through excessive Na+/K+-ATPase inhibition in cardiac and other tissues, including severe nausea, vomiting, diarrhea, abdominal pain, bradycardia, heart block, potentially fatal ventricular arrhythmias, and hyperkalemia. A characteristic and diagnostically useful symptom is xanthopsia—visual disturbances featuring yellow-green halos around light sources—historically thought to have influenced Vincent van Gogh's palette during periods when he may have been treated with digitalis for epilepsy. Children and pets are particularly vulnerable to accidental poisoning from ornamental garden foxglove plants, as all parts of the plant including leaves, flowers, and seeds contain toxic glycosides.
What is the difference between digoxin and digitoxin from foxglove?
Digoxin and digitoxin are both cardenolide cardiac glycosides derived from Digitalis species—digoxin primarily from Digitalis lanata and digitoxin from Digitalis purpurea—but they differ significantly in pharmacokinetics. Digitoxin is highly lipophilic, undergoes extensive hepatic metabolism with a half-life of 5–7 days, and is not renally cleared, making it potentially safer in kidney disease but requiring careful hepatic function monitoring. Digoxin has approximately 70% oral bioavailability, a half-life of 36–48 hours, and is primarily renally excreted, necessitating dose adjustment in renal impairment; digoxin is the dominant clinical choice in contemporary medicine due to its more predictable monitoring profile.
Does foxglove interact with common heart medications like beta-blockers or ACE inhibitors?
Foxglove-derived cardiac glycosides (digoxin and digitoxin) can have significant interactions with beta-blockers, calcium channel blockers, and diuretics, potentially increasing toxicity risk or altering therapeutic effects. ACE inhibitors may increase digoxin levels by reducing renal clearance, requiring dose adjustment and careful monitoring. Any combination of foxglove derivatives with other cardiac medications should only be managed under direct medical supervision with regular serum level monitoring.
Who should avoid foxglove supplements, and are there specific populations at higher risk for adverse effects?
Foxglove should be avoided by pregnant and breastfeeding women, children, elderly patients with renal impairment, and individuals with hypokalemia, hypomagnesemia, or hypercalcemia, as these conditions significantly increase toxicity risk. Patients with certain arrhythmias (such as Wolff-Parkinson-White syndrome), severe kidney disease, or acute myocardial infarction face elevated danger from cardiac glycoside accumulation. Self-supplementation with foxglove is contraindicated; only pharmaceutical-grade digoxin and digitoxin under medical prescription should be considered.
What does clinical research show about foxglove's effectiveness compared to modern heart failure medications?
Historical landmark trials like the DIG trial (Digitalis Investigation Group) demonstrated that digoxin improves symptoms and reduces hospitalizations in heart failure but does not reduce mortality compared to placebo or modern agents like ACE inhibitors and beta-blockers. Contemporary clinical evidence favors newer medications with mortality benefits, relegating digoxin primarily to rate control in atrial fibrillation or symptomatic relief in specific heart failure subsets. Foxglove glycosides remain valuable in certain cardiac conditions but are no longer first-line therapy due to superior safety and efficacy profiles of alternative medications.
Explore the Full Encyclopedia
7,400+ ingredients researched, verified, and formulated for optimal synergy.
Browse IngredientsThese statements have not been evaluated by the Food and Drug Administration. This content is for informational purposes only and is not intended to diagnose, treat, cure, or prevent any disease.
hermetica-encyclopedia-canary-zzqv9k4w foxglove-digitalis-purpurea curated by Hermetica Superfoods at ingredients.hermeticasuperfoods.com and licensed CC BY-NC-SA 4.0 (non-commercial share-alike, attribution required)
